homovanillic acid has been researched along with Disease Models, Animal in 195 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study assessed behaviour, as measured by 50kHz calls related to positive affect, in rats with different fear conditioned response strengths: low-anxiety rats (LR) and high-anxiety rats (HR), after amphetamine injection in a two-injection protocol (TIPS)." | 7.80 | High-anxiety rats are less sensitive to the rewarding affects of amphetamine on 50kHz USV. ( Kaniuga, E; Lehner, MH; Płaźnik, A; Skórzewska, A; Sobolewska, A; Taracha, E; Turzyńska, D; Wisłowska-Stanek, A; Wróbel, J, 2014) |
| "The fact that amphetamine, a noradrenaline releaser, prevents motion sickness leads the hypothesis of Wood and Graybiel that the noradrenergic neuron system in the brain stem acts against the development of motion sickness." | 7.68 | Catecholaminergic responses to rotational stress in rat brain stem: implications for amphetamine therapy of motion sickness. ( Matsunaga, T; Morita, M; Takeda, N; Wada, H; Yamatodani, A, 1990) |
| "In the murine model of early Parkinson's disease, the balance between dopamine and 5-hydroxytryptamine systems varied among brain regions." | 5.91 | Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease. ( He, L; Huang, H; Shi, J; Xie, S; Yang, R; Yang, Y; Ye, S; Zhang, S; Zhang, Y, 2023) |
| "This study assessed behaviour, as measured by 50kHz calls related to positive affect, in rats with different fear conditioned response strengths: low-anxiety rats (LR) and high-anxiety rats (HR), after amphetamine injection in a two-injection protocol (TIPS)." | 3.80 | High-anxiety rats are less sensitive to the rewarding affects of amphetamine on 50kHz USV. ( Kaniuga, E; Lehner, MH; Płaźnik, A; Skórzewska, A; Sobolewska, A; Taracha, E; Turzyńska, D; Wisłowska-Stanek, A; Wróbel, J, 2014) |
| "The aim of this work was to analyze the effect of oxcarbazepine (OXC) on sleep patterns, "head and body shakes" and monoamine neurotransmitters level in a model of kainic-induced seizures." | 3.77 | Effects of oxcarbazepine on monoamines content in hippocampus and head and body shakes and sleep patterns in kainic acid-treated rats. ( Alfaro-Rodríguez, A; Arch-Tirado, E; Ávila-Luna, A; Bueno-Nava, A; González-Piña, R; Uribe-Escamilla, R; Vargas-Sánchez, J, 2011) |
| "To develop a mouse model to mimic the behavioral and neurochemical changes of Tourette syndrome (TS) by 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) induction and to investigate the effects of fluoxetine and haloperidol on head twitch response (HTR) induced by DOI." | 3.74 | [Roles of fluoxetine and haloperidol in mouse models of DOI-induced head twitch response]. ( Dai, XM; Lu, Y; Ma, HW; Yao, Y, 2007) |
| " N-Methyl(R)salsolinol induced DNA damage to human neuroblastoma SH-SY5Y cells, which could be prevented by anti-oxidants and cycloheximide." | 3.70 | Oxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines. ( Dostert, P; Kasamatsu, T; Maruyama, W; Naoi, M, 1998) |
| "The long-term effect of the parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central monoaminergic neurons in young (2-3 months) and aging (12 months) C57BL/6 mice has been studied using neurochemical and immunocytochemical techniques." | 3.68 | Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. ( Date, I; Felten, DL; Felten, SY, 1990) |
| "The fact that amphetamine, a noradrenaline releaser, prevents motion sickness leads the hypothesis of Wood and Graybiel that the noradrenergic neuron system in the brain stem acts against the development of motion sickness." | 3.68 | Catecholaminergic responses to rotational stress in rat brain stem: implications for amphetamine therapy of motion sickness. ( Matsunaga, T; Morita, M; Takeda, N; Wada, H; Yamatodani, A, 1990) |
| "In the murine model of early Parkinson's disease, the balance between dopamine and 5-hydroxytryptamine systems varied among brain regions." | 1.91 | Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease. ( He, L; Huang, H; Shi, J; Xie, S; Yang, R; Yang, Y; Ye, S; Zhang, S; Zhang, Y, 2023) |
| "Schizophrenia is probably ascribed to perinatal neurodevelopmental deficits, and its onset might be affected by environmental factors." | 1.62 | Preventive role of regular low-intensity exercise during adolescence in schizophrenia model mice with abnormal behaviors. ( Hata, T; Hiraga, T; Koizumi, H; Mouri, A; Nabeshima, T; Oharomari, LK; Okamoto, M; Shima, T; Soya, H; Yook, JS, 2021) |
| "In a model of Parkinson's disease we demonstrate that repeated short-term expression of GDNF restores motor capabilities in 6-OHDA-lesioned rats." | 1.48 | Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. ( Bähr, M; Cheng, S; Déglon, N; Konstantinova, P; Kügler, S; Liefhebber, J; Mazur, A; Pythoud, C; Raina, A; Rey, M; Streit, F; Tereshchenko, J; Vachey, G; Zimmer, V, 2018) |
| "Current research on Parkinson's disease (PD) pathogenesis requires relevant animal models that mimic the gradual and progressive development of neuronal dysfunction and degeneration that characterizes the disease." | 1.42 | Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. ( Beauvais, G; Brundin, P; Escobar Galvis, ML; Feinstein, TN; Fuchs, J; Ghosh, A; Joshi, RL; Lipton, JW; Lundblad, M; Medicetty, S; Nordströma, U; Prochiantz, A; Pulikkaparambil Sasidharan, BC; Roholt, A; Steiner, JA, 2015) |
| "We have previously shown that food allergy impaired social behaviour in mice." | 1.42 | Dietary long chain n-3 polyunsaturated fatty acids prevent impaired social behaviour and normalize brain dopamine levels in food allergic mice. ( Broersen, LM; de Theije, CG; Garssen, J; Korte, SM; Korte-Bouws, GA; Kraneveld, AD; Lopes da Silva, S; Milosevic, V; Olivier, B; van den Elsen, LW; Willemsen, LE, 2015) |
| "Food allergy has been suggested to contribute to the expression of psychological and psychiatric traits, including disturbed social behaviour and repetitive behaviour inherent in autism spectrum disorders (ASD)." | 1.40 | Autistic-like behavioural and neurochemical changes in a mouse model of food allergy. ( Borre, Y; de Theije, CG; Garssen, J; Kas, MJ; Koelink, PJ; Korte, SM; Korte-Bouws, GA; Kraneveld, AD; Lopes da Silva, S; Olivier, B; Wu, J, 2014) |
| "α-Syn fibrils intensified not only the hypokinesia and immobility 14 days post treatment, but also reduced vertical rearing and enhanced DA levels in the substantia nigra." | 1.40 | Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates. ( Davydova, TV; Fomina, VG; Gruden, MA; Kudrin, VS; Morozova-Roche, LA; Narkevich, VB; Sewell, RD; Wang, C, 2014) |
| "Post-Traumatic Stress Disorder (PTSD) can develop in response to a traumatic event involving a threat to life." | 1.40 | Predator exposure/psychosocial stress animal model of post-traumatic stress disorder modulates neurotransmitters in the rat hippocampus and prefrontal cortex. ( Ebenezer, PJ; Francis, J; McLaughlin, LD; Wilson, CB, 2014) |
| "ADHs are of interest in Parkinson's disease (PD) since these compounds can be harmful to dopamine (DA) neurons." | 1.38 | Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease. ( Anvret, A; Belin, AC; Duester, G; Felder, MR; Galter, D; Gellhaar, S; Lindqvist, E; Lundströmer, K; Pernold, K; Ran, C; Westerlund, M, 2012) |
| "Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder of mature and older individuals." | 1.36 | Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. ( Charlton, CG; King, J; Mackey, V; Muthian, G, 2010) |
| " Acute or chronic administration of methamphetamine elevates the levels of the extracellular monoamine neurotransmitters, such as dopamine." | 1.35 | Prenatal methamphetamine exposure affects the mesolimbic dopaminergic system and behavior in adult offspring. ( Bubenikova-Valesova, V; Hruba, L; Janovsky, M; Kacer, P; Rambousek, L; Schutova, B; Slamberova, R; Syslova, K, 2009) |
| "Memantine was administered two weeks post infection, at peak viremia, in order to prevent early NMDA receptor activation due to immune mediators." | 1.35 | Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. ( Kneitz, S; Koutsilieri, E; Meisner, F; Neuen-Jacob, E; Riederer, P; Scheller, C; Sopper, S; ter Meulen, V, 2008) |
| " Because of their ability to combat oxidative stress, diet derived phenolic compounds continue to be considered as potential agents for long-term use in PD." | 1.33 | Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. ( Aruoma, OI; Datla, KP; Dexter, DT; Parkar, S; Rai, DK; Zbarsky, V, 2005) |
| " Therefore, the aim of the present study was to examine whether the long-term administration of a commonly used herbicide, paraquat, which has already been found to induce a slowly progressing degeneration of the nigrostriatal neurons, influences mesocortical dopaminergic neurons in rats." | 1.33 | Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. ( Biedka, I; Bortel, A; Dabrowska, J; Kuter, K; Nowak, P; Ossowska, K; Rommelspacher, H; Schulze, G; Smiałowska, M; Wardas, J; Wierońska, J; Zieba, B, 2006) |
| "Dopaminergic lesion produced catalepsy and hypoactivity." | 1.32 | Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. ( Schmidt, WJ; Srinivasan, J, 2004) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| "Tolcapone treatment enhanced CSF DOPAC concentrations in unlesioned animals (by approximately four times) as well as monkeys rendered parkinsonian after severe nigrostriatal dopaminergic injury caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.32 | Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. ( Di Monte, DA; Langston, JW; Thiffault, C, 2003) |
| " Although increasing the dosage of d-METH (20 to 80 mg/kg) did increase the GFAP response (100% over control), it was still well below that usually exhibited at the usual neurotoxic dosage (300-400% over control) in fully mature mice." | 1.31 | Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure. ( Ali, SF; Miller, DB; O'Callaghan, JP, 2000) |
| "The hyperphagia was further enhanced when they were put in a space-restricted cage where their mobility was restricted." | 1.30 | Prefrontal and striatal dopamine metabolism during enhanced rebound hyperphagia induced by space restriction--a rat model of binge eating. ( Fujisaki, Y; Inoue, K; Iwasaki, S; Kiriike, N; Kurioka, M; Okuno, M; Yamagami, S, 1998) |
| "Investigations of gene therapy for Parkinson's disease have focused primarily on strategies that replace tyrosine hydroxylase." | 1.30 | Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. ( Bencsics, C; Kang, UJ; Wachtel, SR, 1997) |
| "That thalidomide has activity in this model suggests that an inflammatory process may be involved in the induction of lesions by MPTP in DAergic neurons." | 1.30 | Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. ( Boireau, A; Bordier, F; Dubédat, P; Impérato, A; Pény, C, 1997) |
| "The behavioural, biochemical and morphological effects of a chronic administration of low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were studied in the common marmoset." | 1.29 | Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. ( Albanese, A; Colosimo, C; Granata, R; Gregori, B; Piccardi, MP; Tonali, P, 1993) |
| "The homovanillic acid content was significantly increased in the hypothalamus, hippocampus/substantia nigra and brainstem." | 1.29 | Tyrosine uptake and regional brain monoamine metabolites in a rat model resembling congenital hyperammonemia. ( Bachmann, C; Cervantes, H; Colombo, JP; Kokorovic, M; Perritaz, R, 1996) |
| "In ongoing studies of chronic administration of neuroleptics to monkeys (Cebus apella) and rats, the regional distribution of glutamic acid decarboxylase (GAD) and brain levels of homovanillic acid were examined." | 1.27 | Experimental tardive dyskinesia. ( Gunne, LM; Häggström, JE, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (12.82) | 18.7374 |
| 1990's | 24 (12.31) | 18.2507 |
| 2000's | 82 (42.05) | 29.6817 |
| 2010's | 59 (30.26) | 24.3611 |
| 2020's | 5 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Ohtsuki, S | 1 |
| Kikkawa, T | 1 |
| Mori, S | 1 |
| Hori, S | 1 |
| Takanaga, H | 1 |
| Otagiri, M | 1 |
| Terasaki, T | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Tian, P | 1 |
| Zhang, W | 1 |
| Li, KY | 1 |
| Li, HW | 1 |
| Ma, K | 1 |
| Han, DE | 1 |
| Yang, R | 1 |
| Ye, S | 1 |
| Zhang, S | 1 |
| Huang, H | 1 |
| Zhang, Y | 1 |
| Yang, Y | 2 |
| Xie, S | 1 |
| He, L | 1 |
| Shi, J | 1 |
| Thakur, V | 1 |
| Jamwal, S | 1 |
| Kumar, M | 1 |
| Rahi, V | 1 |
| Kumar, P | 1 |
| Koizumi, H | 1 |
| Hiraga, T | 1 |
| Oharomari, LK | 1 |
| Hata, T | 1 |
| Shima, T | 1 |
| Yook, JS | 1 |
| Okamoto, M | 1 |
| Mouri, A | 1 |
| Nabeshima, T | 1 |
| Soya, H | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Romańska, I | 1 |
| Wąsik, A | 1 |
| Michaluk, J | 1 |
| Liu, J | 1 |
| Zheng, F | 1 |
| Long, Y | 1 |
| Tong, L | 1 |
| Zheng, Y | 1 |
| Liu, X | 2 |
| Qin, C | 1 |
| Miner, NB | 1 |
| Elmore, JS | 1 |
| Baumann, MH | 1 |
| Phillips, TJ | 1 |
| Janowsky, A | 1 |
| Luo, X | 1 |
| Li, B | 1 |
| Li, T | 1 |
| Di, Y | 1 |
| Zheng, C | 1 |
| Ji, S | 1 |
| Ma, Y | 1 |
| Zhu, J | 1 |
| Chen, X | 1 |
| Zhou, X | 1 |
| Moreno-Galarza, N | 1 |
| Mendieta, L | 1 |
| Palafox-Sánchez, V | 1 |
| Herrando-Grabulosa, M | 1 |
| Gil, C | 1 |
| Limón, DI | 1 |
| Aguilera, J | 1 |
| Cheng, S | 1 |
| Tereshchenko, J | 1 |
| Zimmer, V | 1 |
| Vachey, G | 1 |
| Pythoud, C | 1 |
| Rey, M | 1 |
| Liefhebber, J | 1 |
| Raina, A | 1 |
| Streit, F | 1 |
| Mazur, A | 1 |
| Bähr, M | 4 |
| Konstantinova, P | 1 |
| Déglon, N | 1 |
| Kügler, S | 1 |
| Chu, X | 1 |
| Jones, BC | 2 |
| Miller, DB | 3 |
| O'Callaghan, JP | 3 |
| Lu, L | 2 |
| Unger, EL | 1 |
| Alam, G | 2 |
| Williams, RW | 2 |
| Petri, D | 1 |
| Pum, M | 1 |
| Vesper, J | 1 |
| Huston, JP | 4 |
| Schnitzler, A | 1 |
| Rodríguez-Arias, M | 1 |
| Valverde, O | 1 |
| Daza-Losada, M | 1 |
| Blanco-Gandía, MC | 1 |
| Aguilar, MA | 1 |
| Miñarro, J | 1 |
| Yamamoto, T | 1 |
| Uchiyama, T | 1 |
| Sakakibara, R | 1 |
| Taniguchi, J | 1 |
| Kuwabara, S | 1 |
| de Theije, CG | 2 |
| Wu, J | 1 |
| Koelink, PJ | 1 |
| Korte-Bouws, GA | 3 |
| Borre, Y | 1 |
| Kas, MJ | 1 |
| Lopes da Silva, S | 2 |
| Korte, SM | 4 |
| Olivier, B | 2 |
| Garssen, J | 2 |
| Kraneveld, AD | 2 |
| Gruden, MA | 1 |
| Davydova, TV | 1 |
| Narkevich, VB | 1 |
| Fomina, VG | 1 |
| Wang, C | 1 |
| Kudrin, VS | 1 |
| Morozova-Roche, LA | 1 |
| Sewell, RD | 1 |
| Wilson, CB | 1 |
| Ebenezer, PJ | 1 |
| McLaughlin, LD | 1 |
| Francis, J | 1 |
| Miao, SH | 1 |
| Sun, HB | 1 |
| Ye, Y | 1 |
| Yang, JJ | 1 |
| Shi, YW | 1 |
| Lu, M | 1 |
| Hu, G | 1 |
| Zhou, JW | 1 |
| Jiang, H | 1 |
| Li, F | 1 |
| Liu, S | 1 |
| Sun, H | 1 |
| Cui, Y | 1 |
| Wu, Y | 1 |
| Rose, KM | 1 |
| Parmar, MS | 1 |
| Cavanaugh, JE | 1 |
| Feng, G | 1 |
| Zhang, Z | 2 |
| Bao, Q | 1 |
| Zhou, L | 1 |
| Jiang, J | 1 |
| Li, S | 1 |
| Pifl, C | 1 |
| Rajput, A | 1 |
| Reither, H | 1 |
| Blesa, J | 1 |
| Cavada, C | 1 |
| Obeso, JA | 1 |
| Rajput, AH | 1 |
| Hornykiewicz, O | 1 |
| Morin, N | 1 |
| Morissette, M | 2 |
| Grégoire, L | 1 |
| Di Paolo, T | 1 |
| Han, B | 1 |
| Jin, HJ | 1 |
| Song, MY | 1 |
| Wang, T | 1 |
| Zhao, H | 1 |
| Lehner, MH | 1 |
| Taracha, E | 1 |
| Kaniuga, E | 1 |
| Wisłowska-Stanek, A | 1 |
| Wróbel, J | 1 |
| Sobolewska, A | 1 |
| Turzyńska, D | 1 |
| Skórzewska, A | 1 |
| Płaźnik, A | 1 |
| Zhang, F | 1 |
| Li, A | 1 |
| Nordströma, U | 1 |
| Beauvais, G | 1 |
| Ghosh, A | 1 |
| Pulikkaparambil Sasidharan, BC | 1 |
| Lundblad, M | 1 |
| Fuchs, J | 1 |
| Joshi, RL | 1 |
| Lipton, JW | 1 |
| Roholt, A | 1 |
| Medicetty, S | 1 |
| Feinstein, TN | 1 |
| Steiner, JA | 1 |
| Escobar Galvis, ML | 1 |
| Prochiantz, A | 1 |
| Brundin, P | 1 |
| Saal, KA | 1 |
| Koch, JC | 1 |
| Tatenhorst, L | 1 |
| Szegő, EM | 1 |
| Ribas, VT | 1 |
| Michel, U | 1 |
| Tönges, L | 1 |
| Lingor, P | 2 |
| van den Elsen, LW | 1 |
| Willemsen, LE | 1 |
| Milosevic, V | 1 |
| Broersen, LM | 1 |
| Willard, AM | 1 |
| Bouchard, RS | 1 |
| Gittis, AH | 1 |
| Sharma, N | 1 |
| Nehru, B | 1 |
| Chen, S | 1 |
| Zhang, XJ | 1 |
| Xie, WJ | 1 |
| Qiu, HY | 1 |
| Liu, H | 1 |
| Le, WD | 1 |
| Iuvone, PM | 1 |
| Haque, R | 1 |
| Fernandes, A | 1 |
| Lambert, SR | 1 |
| Winn, SR | 1 |
| Scherer, T | 1 |
| Thöny, B | 1 |
| Harding, CO | 1 |
| Hirth, N | 1 |
| Meinhardt, MW | 1 |
| Noori, HR | 1 |
| Salgado, H | 1 |
| Torres-Ramirez, O | 1 |
| Uhrig, S | 1 |
| Broccoli, L | 1 |
| Vengeliene, V | 1 |
| Roßmanith, M | 1 |
| Perreau-Lenz, S | 1 |
| Köhr, G | 1 |
| Sommer, WH | 1 |
| Spanagel, R | 1 |
| Hansson, AC | 1 |
| Milienne-Petiot, M | 1 |
| Kesby, JP | 1 |
| Graves, M | 1 |
| van Enkhuizen, J | 1 |
| Semenova, S | 1 |
| Minassian, A | 1 |
| Markou, A | 1 |
| Geyer, MA | 1 |
| Young, JW | 1 |
| Boulet, S | 1 |
| Mounayar, S | 1 |
| Poupard, A | 1 |
| Bertrand, A | 1 |
| Jan, C | 1 |
| Pessiglione, M | 1 |
| Hirsch, EC | 3 |
| Feuerstein, C | 1 |
| François, C | 1 |
| Féger, J | 1 |
| Savasta, M | 1 |
| Tremblay, L | 1 |
| Xu, L | 1 |
| Liu, LX | 2 |
| Chen, WF | 2 |
| Samanta, SK | 1 |
| Kumar, KT | 1 |
| Roy, A | 1 |
| Karmakar, S | 1 |
| Lahiri, S | 1 |
| Palit, G | 1 |
| Vedasiromoni, JR | 1 |
| Sen, T | 1 |
| Verhagen, LA | 1 |
| Luijendijk, MC | 1 |
| Adan, RA | 1 |
| Kraft, JC | 1 |
| Osterhaus, GL | 1 |
| Ortiz, AN | 1 |
| Garris, PA | 1 |
| Johnson, MA | 1 |
| Samad, N | 1 |
| Haleem, DJ | 1 |
| Hamasu, K | 1 |
| Shigemi, K | 1 |
| Kabuki, Y | 1 |
| Tomonaga, S | 1 |
| Denbow, DM | 1 |
| Furuse, M | 1 |
| Bubenikova-Valesova, V | 1 |
| Kacer, P | 1 |
| Syslova, K | 1 |
| Rambousek, L | 1 |
| Janovsky, M | 1 |
| Schutova, B | 1 |
| Hruba, L | 1 |
| Slamberova, R | 1 |
| Gal, S | 1 |
| Zheng, H | 1 |
| Fridkin, M | 1 |
| Youdim, MB | 2 |
| RajaSankar, S | 1 |
| Manivasagam, T | 1 |
| Sankar, V | 1 |
| Prakash, S | 1 |
| Muthusamy, R | 1 |
| Krishnamurti, A | 1 |
| Surendran, S | 1 |
| Zádori, D | 1 |
| Geisz, A | 1 |
| Vámos, E | 1 |
| Vécsei, L | 1 |
| Klivényi, P | 4 |
| Kim, ST | 1 |
| Son, HJ | 1 |
| Choi, JH | 1 |
| Ji, IJ | 1 |
| Hwang, O | 1 |
| Lin, JW | 1 |
| Shih, CM | 1 |
| Chen, YC | 1 |
| Lin, CM | 1 |
| Tsai, JT | 1 |
| Chiang, YH | 1 |
| Shih, R | 1 |
| Chiu, PL | 1 |
| Hung, KS | 1 |
| Yeh, YS | 1 |
| Wei, L | 1 |
| Chiu, WT | 1 |
| Yang, LY | 1 |
| Zhang, HN | 2 |
| An, CN | 1 |
| Pu, XP | 1 |
| Marcellino, D | 1 |
| Suárez-Boomgaard, D | 1 |
| Sánchez-Reina, MD | 1 |
| Aguirre, JA | 1 |
| Yoshitake, T | 1 |
| Yoshitake, S | 1 |
| Hagman, B | 1 |
| Kehr, J | 1 |
| Agnati, LF | 1 |
| Fuxe, K | 1 |
| Rivera, A | 1 |
| Reksidler, AB | 1 |
| Lima, MM | 1 |
| Dombrowski, PA | 1 |
| Barnabé, GF | 1 |
| Andersen, ML | 1 |
| Tufik, S | 1 |
| Vital, MA | 1 |
| Kuroiwa, H | 1 |
| Yokoyama, H | 2 |
| Kimoto, H | 2 |
| Kato, H | 3 |
| Araki, T | 3 |
| Borah, A | 1 |
| Mohanakumar, KP | 1 |
| Muthian, G | 1 |
| Mackey, V | 1 |
| King, J | 1 |
| Charlton, CG | 1 |
| Belin, AC | 2 |
| Westerlund, M | 2 |
| Anvret, A | 2 |
| Lindqvist, E | 2 |
| Pernold, K | 2 |
| Ogren, SO | 1 |
| Duester, G | 2 |
| Galter, D | 2 |
| Sgadò, P | 1 |
| Viaggi, C | 1 |
| Pinna, A | 1 |
| Marrone, C | 1 |
| Vaglini, F | 1 |
| Pontis, S | 1 |
| Mercuri, NB | 1 |
| Morelli, M | 1 |
| Corsini, GU | 1 |
| Bajo-Grañeras, R | 1 |
| Ganfornina, MD | 1 |
| Martín-Tejedor, E | 1 |
| Sanchez, D | 1 |
| Gao, L | 1 |
| Díaz-Martín, J | 1 |
| Dillmann, WH | 1 |
| López-Barneo, J | 1 |
| Alfaro-Rodríguez, A | 1 |
| González-Piña, R | 1 |
| Bueno-Nava, A | 1 |
| Arch-Tirado, E | 1 |
| Ávila-Luna, A | 1 |
| Uribe-Escamilla, R | 1 |
| Vargas-Sánchez, J | 1 |
| Chao, OY | 2 |
| von Bothmer, A | 1 |
| Pum, ME | 2 |
| Wright, HF | 1 |
| Mills, DS | 1 |
| Pollux, PM | 1 |
| Cruz, FC | 1 |
| Marin, MT | 1 |
| Leão, RM | 1 |
| Planeta, CS | 1 |
| Ran, C | 1 |
| Gellhaar, S | 1 |
| Lundströmer, K | 1 |
| Felder, MR | 1 |
| Mattern, C | 1 |
| Silva, AM | 1 |
| Wessler, J | 1 |
| Ruocco, LA | 1 |
| Nikolaus, S | 1 |
| van Bregt, DR | 1 |
| Thomas, TC | 1 |
| Hinzman, JM | 1 |
| Cao, T | 1 |
| Liu, M | 1 |
| Bing, G | 1 |
| Gerhardt, GA | 2 |
| Pauly, JR | 1 |
| Lifshitz, J | 1 |
| Liu, SM | 1 |
| Li, XZ | 1 |
| Huo, Y | 1 |
| Lu, F | 1 |
| Frank, T | 1 |
| Klinker, F | 1 |
| Falkenburger, BH | 1 |
| Laage, R | 2 |
| Lühder, F | 1 |
| Göricke, B | 2 |
| Schneider, A | 2 |
| Neurath, H | 1 |
| Desel, H | 1 |
| Liebetanz, D | 1 |
| Weishaupt, JH | 2 |
| Tanaka, K | 3 |
| Furuyashiki, T | 1 |
| Kitaoka, S | 1 |
| Senzai, Y | 1 |
| Imoto, Y | 1 |
| Segi-Nishida, E | 1 |
| Deguchi, Y | 1 |
| Breyer, RM | 1 |
| Breyer, MD | 1 |
| Narumiya, S | 1 |
| Schumm, S | 1 |
| Sebban, C | 1 |
| Cohen-Salmon, C | 1 |
| Callebert, J | 2 |
| Launay, JM | 2 |
| Golmard, JL | 1 |
| Boussicault, L | 1 |
| Petropoulos, I | 1 |
| Hild, A | 1 |
| Rousselet, E | 1 |
| Prigent, A | 1 |
| Friguet, B | 1 |
| Mariani, J | 1 |
| Choi, DY | 1 |
| Lee, MK | 1 |
| Hong, JT | 1 |
| Lin, L | 1 |
| Meng, T | 1 |
| Liu, T | 1 |
| Zheng, Z | 1 |
| Tillerson, JL | 3 |
| Cohen, AD | 2 |
| Caudle, WM | 2 |
| Zigmond, MJ | 2 |
| Schallert, T | 2 |
| Miller, GW | 4 |
| Breidert, T | 1 |
| Heneka, MT | 1 |
| Landreth, G | 1 |
| Doyle, SE | 1 |
| McIvor, WE | 1 |
| Menaker, M | 1 |
| Reverón, ME | 1 |
| Kurachi, M | 2 |
| Zafar, KS | 1 |
| Siddiqui, A | 1 |
| Sayeed, I | 1 |
| Ahmad, M | 2 |
| Salim, S | 1 |
| Islam, F | 3 |
| De la Fuente, M | 1 |
| Hernanz, A | 1 |
| Medina, S | 1 |
| Guayerbas, N | 1 |
| Fernández, B | 1 |
| Viveros, MP | 1 |
| Schlüter, OM | 1 |
| Fornai, F | 2 |
| Alessandrí, MG | 1 |
| Takamori, S | 1 |
| Geppert, M | 1 |
| Jahn, R | 1 |
| Südhof, TC | 1 |
| Srinivasan, J | 2 |
| Schmidt, WJ | 2 |
| Shimazu, S | 1 |
| Takahata, K | 1 |
| Tamashiro, A | 1 |
| Yoneda, F | 1 |
| Iida, Y | 1 |
| Saji, H | 1 |
| Thiffault, C | 1 |
| Langston, JW | 1 |
| Di Monte, DA | 1 |
| Burke, WJ | 1 |
| Li, SW | 1 |
| Williams, EA | 1 |
| Nonneman, R | 1 |
| Zahm, DS | 1 |
| Lonjon, M | 1 |
| Quentien, MH | 1 |
| Risso, JJ | 1 |
| Michiels, JF | 1 |
| Carre, E | 1 |
| Rostain, JC | 1 |
| Darbin, O | 1 |
| Battaglia, G | 1 |
| Busceti, CL | 1 |
| Molinaro, G | 1 |
| Biagioni, F | 1 |
| Storto, M | 1 |
| Nicoletti, F | 1 |
| Bruno, V | 1 |
| Masini, CV | 1 |
| Holmes, PV | 1 |
| Freeman, KG | 1 |
| Maki, AC | 1 |
| Edwards, GL | 1 |
| Stephenson, G | 1 |
| Ben Shachar, D | 1 |
| Gluck, MR | 1 |
| Santana, LA | 1 |
| Granson, H | 1 |
| Yahr, MD | 1 |
| van Hierden, YM | 1 |
| de Boer, SF | 1 |
| Koolhaas, JM | 1 |
| Leng, A | 1 |
| Mura, A | 1 |
| Hengerer, B | 1 |
| Feldon, J | 1 |
| Ferger, B | 5 |
| Ogawa, N | 2 |
| Shimoji, M | 1 |
| Zhang, L | 1 |
| Mandir, AS | 1 |
| Dawson, VL | 1 |
| Dawson, TM | 1 |
| Gardian, G | 1 |
| Calingasan, NY | 2 |
| Yang, L | 2 |
| von Borstel, R | 1 |
| Saydoff, J | 1 |
| Browne, SE | 1 |
| Beal, MF | 5 |
| Asanuma, M | 1 |
| Miyazaki, I | 1 |
| Diaz-Corrales, FJ | 1 |
| Shimizu, M | 1 |
| Ahmad, AS | 1 |
| Ansari, MA | 1 |
| Saleem, S | 1 |
| Yousuf, S | 1 |
| Hoda, MN | 1 |
| Dang, MT | 1 |
| Yokoi, F | 1 |
| McNaught, KS | 1 |
| Jengelley, TA | 1 |
| Jackson, T | 1 |
| Li, J | 1 |
| Li, Y | 1 |
| Zbarsky, V | 1 |
| Datla, KP | 1 |
| Parkar, S | 1 |
| Rai, DK | 1 |
| Aruoma, OI | 1 |
| Dexter, DT | 1 |
| Glaser, PE | 1 |
| Surgener, SP | 1 |
| Grondin, R | 1 |
| Gash, CR | 1 |
| Palmer, M | 1 |
| Castellanos, FX | 1 |
| Fitzsimmons, DF | 1 |
| Moloney, TC | 1 |
| Dowd, E | 1 |
| Klejbor, I | 1 |
| Myers, JM | 1 |
| Hausknecht, K | 1 |
| Corso, TD | 1 |
| Gambino, AS | 1 |
| Morys, J | 1 |
| Maher, PA | 1 |
| Hard, R | 1 |
| Richards, J | 1 |
| Stachowiak, EK | 1 |
| Stachowiak, MK | 1 |
| Meuer, K | 1 |
| Pitzer, C | 1 |
| Teismann, P | 3 |
| Krüger, C | 1 |
| Peters, K | 1 |
| Schlachetzki, JC | 1 |
| Kobayashi, K | 1 |
| Dietz, GP | 1 |
| Weber, D | 1 |
| Schäbitz, WR | 1 |
| Bach, A | 1 |
| Schulz, JB | 1 |
| Ossowska, K | 1 |
| Smiałowska, M | 1 |
| Kuter, K | 1 |
| Wierońska, J | 1 |
| Zieba, B | 1 |
| Wardas, J | 1 |
| Nowak, P | 1 |
| Dabrowska, J | 1 |
| Bortel, A | 1 |
| Biedka, I | 1 |
| Schulze, G | 1 |
| Rommelspacher, H | 1 |
| Gardner, EL | 1 |
| Paredes, W | 1 |
| Giordano, A | 1 |
| Spector, J | 1 |
| Lepore, M | 1 |
| Wu, KM | 1 |
| Froimowitz, M | 1 |
| Landau, AM | 1 |
| Kouassi, E | 1 |
| Siegrist-Johnstone, R | 1 |
| Desbarats, J | 1 |
| Malkesman, O | 1 |
| Shayit, M | 1 |
| Genud, R | 1 |
| Zangen, A | 2 |
| Kinor, N | 2 |
| Maayan, R | 1 |
| Weizman, A | 1 |
| Weller, A | 2 |
| Yadid, G | 3 |
| Buck, K | 1 |
| Lavi-Avnon, Y | 1 |
| Finberg, JP | 1 |
| Gispan-Herman, I | 1 |
| Stern, Y | 1 |
| Schroeder, M | 1 |
| Gelber, V | 1 |
| Bergman, SY | 1 |
| Overstreet, DH | 2 |
| Yao, Y | 1 |
| Ma, HW | 1 |
| Lu, Y | 1 |
| Dai, XM | 1 |
| Meisner, F | 1 |
| Scheller, C | 1 |
| Kneitz, S | 1 |
| Sopper, S | 1 |
| Neuen-Jacob, E | 1 |
| Riederer, P | 3 |
| ter Meulen, V | 1 |
| Koutsilieri, E | 1 |
| Xie, JX | 1 |
| Wong, MS | 1 |
| Takagi, S | 1 |
| Watanabe, Y | 1 |
| Lorenzo, BJ | 1 |
| Kadoguchi, N | 1 |
| Yano, R | 1 |
| Blanchet, J | 1 |
| Longpré, F | 1 |
| Bureau, G | 1 |
| DiPaolo, T | 1 |
| Bronchti, G | 1 |
| Martinoli, MG | 1 |
| Melamed, E | 2 |
| Hefti, F | 2 |
| Liebman, J | 1 |
| Schlosberg, AJ | 1 |
| Wurtman, RJ | 3 |
| Mefford, IN | 2 |
| Baker, TL | 1 |
| Boehme, R | 1 |
| Foutz, AS | 1 |
| Ciaranello, RD | 1 |
| Barchas, JD | 1 |
| Dement, WC | 1 |
| Burns, RS | 1 |
| Chiueh, CC | 2 |
| Markey, SP | 1 |
| Ebert, MH | 2 |
| Jacobowitz, DM | 2 |
| Kopin, IJ | 3 |
| Kraemer, GW | 1 |
| Lake, CR | 1 |
| McKinney, WT | 1 |
| Diamond, A | 1 |
| Ciaramitaro, V | 1 |
| Donner, E | 1 |
| Djali, S | 1 |
| Robinson, MB | 1 |
| Amalric, M | 1 |
| Moukhles, H | 1 |
| Nieoullon, A | 1 |
| Daszuta, A | 1 |
| Pastuszko, A | 1 |
| Lajevardi, NS | 1 |
| Huang, CC | 1 |
| Tammela, O | 1 |
| Delivoria-Papadopoulos, M | 1 |
| Wilson, DF | 1 |
| Albanese, A | 1 |
| Granata, R | 1 |
| Gregori, B | 1 |
| Piccardi, MP | 1 |
| Colosimo, C | 1 |
| Tonali, P | 1 |
| Hossain, MA | 1 |
| Weiner, N | 1 |
| Rossetti, ZL | 1 |
| Lai, M | 1 |
| Hmaidan, Y | 1 |
| Gessa, GL | 1 |
| Colombo, JP | 1 |
| Bachmann, C | 1 |
| Cervantes, H | 1 |
| Kokorovic, M | 1 |
| Perritaz, R | 1 |
| Hantraye, P | 1 |
| Brouillet, E | 1 |
| Ferrante, R | 1 |
| Palfi, S | 1 |
| Dolan, R | 1 |
| Matthews, RT | 1 |
| Higley, JD | 1 |
| Suomi, SJ | 1 |
| Linnoila, M | 1 |
| Wachtel, SR | 1 |
| Bencsics, C | 1 |
| Kang, UJ | 1 |
| Boireau, A | 2 |
| Bordier, F | 1 |
| Dubédat, P | 1 |
| Pény, C | 1 |
| Impérato, A | 1 |
| Naoi, M | 1 |
| Maruyama, W | 1 |
| Kasamatsu, T | 1 |
| Dostert, P | 1 |
| Cheng, FC | 1 |
| Ni, DR | 1 |
| Wu, MC | 1 |
| Kuo, JS | 1 |
| Chia, LG | 1 |
| Blanchet, PJ | 1 |
| Konitsiotis, S | 1 |
| Hyland, K | 1 |
| Arnold, LA | 1 |
| Pettigrew, KD | 1 |
| Chase, TN | 1 |
| Inoue, K | 1 |
| Kiriike, N | 1 |
| Okuno, M | 1 |
| Fujisaki, Y | 1 |
| Kurioka, M | 1 |
| Iwasaki, S | 1 |
| Yamagami, S | 1 |
| Dethy, S | 1 |
| Laute, MA | 1 |
| Damhaut, P | 1 |
| Goldman, S | 1 |
| Earl, CD | 1 |
| Kuschinsky, K | 1 |
| Oertel, WH | 1 |
| Andreassen, OA | 2 |
| Ferrante, RJ | 2 |
| Dedeoglu, A | 2 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Andersen, JK | 1 |
| Jiang, D | 1 |
| Elsworth, JD | 2 |
| Taylor, JR | 1 |
| Sladek, JR | 2 |
| Collier, TJ | 2 |
| Redmond, DE | 2 |
| Roth, RH | 2 |
| Reader, TA | 2 |
| Ase, AR | 2 |
| Le Marec, N | 1 |
| Lalonde, R | 1 |
| Heim, C | 1 |
| Zhang, J | 1 |
| Lan, J | 1 |
| Sieklucka, M | 1 |
| Kurz, T | 1 |
| Gerlach, M | 2 |
| Sontag, KH | 1 |
| Uehara, T | 1 |
| Tanii, Y | 1 |
| Sumiyoshi, T | 1 |
| Puglisi-Allegra, S | 2 |
| Cabib, S | 2 |
| Pascucci, T | 1 |
| Ventura, R | 2 |
| Cali, F | 1 |
| Romano, V | 1 |
| Ongali, B | 1 |
| Hébert, C | 1 |
| Amdiss, F | 1 |
| Xue, YL | 1 |
| Wang, ZF | 1 |
| Zhong, DG | 1 |
| Cui, X | 1 |
| Li, XJ | 1 |
| Ma, XJ | 1 |
| Wang, LN | 1 |
| Zhu, K | 1 |
| Sun, AM | 1 |
| Bezard, E | 2 |
| Jaber, M | 1 |
| Gonon, F | 1 |
| Bloch, B | 1 |
| Gross, CE | 2 |
| Imam, SZ | 1 |
| Itzhak, Y | 2 |
| Slikker, W | 2 |
| Ali, SF | 4 |
| Albers, DW | 1 |
| Carlson, EJ | 1 |
| Epstein, CJ | 1 |
| Hofele, K | 1 |
| Sedelis, M | 1 |
| Auburger, GW | 1 |
| Morgan, S | 1 |
| Schwarting, RK | 1 |
| Clarkson, ED | 1 |
| Zawada, WM | 1 |
| Bell, KP | 1 |
| Esplen, JE | 1 |
| Choi, PK | 1 |
| Heidenreich, KA | 1 |
| Freed, CR | 1 |
| Zhuang, X | 1 |
| Oosting, RS | 1 |
| Jones, SR | 1 |
| Gainetdinov, RR | 1 |
| Caron, MG | 1 |
| Hen, R | 1 |
| Pestana, M | 1 |
| Jardim, H | 1 |
| Correia, F | 1 |
| Vieira-Coelho, MA | 1 |
| Soares-da-Silva, P | 1 |
| Philhower, J | 1 |
| Dovero, S | 1 |
| Prunier, C | 1 |
| Ravenscroft, P | 1 |
| Chalon, S | 1 |
| Guilloteau, D | 1 |
| Crossman, AR | 1 |
| Bioulac, B | 1 |
| Brotchie, JM | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Barthwal, MK | 1 |
| Srivastava, N | 1 |
| Dikshit, M | 1 |
| Binienda, ZK | 1 |
| Pereira, F | 1 |
| Alper, K | 1 |
| Bareggi, SR | 1 |
| Becker, RE | 1 |
| Ginsburg, BE | 1 |
| Genovese, E | 1 |
| Moskowitz, MA | 1 |
| Poirier, L | 1 |
| Filion, M | 1 |
| Langelier, P | 1 |
| Larochelle, L | 1 |
| Anokhina, IP | 1 |
| Gamaleia, NB | 1 |
| Benhar, E | 1 |
| Sayers, AC | 2 |
| Bürki, HR | 2 |
| Ruch, W | 2 |
| Asper, H | 2 |
| Poirier, LJ | 1 |
| Parent, A | 1 |
| Roberge, AG | 1 |
| Lycke, E | 2 |
| Roos, BE | 2 |
| García Ruiz, PJ | 1 |
| Mena, MA | 1 |
| Peñafiel, N | 1 |
| De Yébenes, JG | 1 |
| Gurguis, GN | 1 |
| Klein, E | 1 |
| Uhde, TW | 1 |
| Bankiewicz, KS | 2 |
| Plunkett, RJ | 1 |
| Mefford, I | 1 |
| Oldfield, EH | 2 |
| Russ, H | 2 |
| Mihatsch, W | 1 |
| Przuntek, H | 2 |
| Johansson, PE | 1 |
| Terenius, L | 1 |
| Häggström, JE | 2 |
| Gunne, L | 1 |
| Date, I | 1 |
| Felten, DL | 1 |
| Felten, SY | 1 |
| Takeda, N | 1 |
| Morita, M | 1 |
| Yamatodani, A | 1 |
| Wada, H | 1 |
| Matsunaga, T | 1 |
| del Ser, T | 1 |
| Franch, O | 1 |
| Portera, A | 1 |
| Muradas, V | 1 |
| Yebenes, JG | 1 |
| Brown, GL | 1 |
| Goodwin, FK | 1 |
| Murphy, JM | 1 |
| McBride, WJ | 1 |
| Lumeng, L | 1 |
| Li, TK | 1 |
| Henning, K | 1 |
| Eckhardt, H | 1 |
| Gunne, LM | 1 |
| Perry, TL | 1 |
| Yong, VW | 1 |
| Ito, M | 1 |
| Jones, K | 1 |
| Wall, RA | 1 |
| Foulks, JG | 1 |
| Wright, JM | 1 |
| Kish, SJ | 1 |
| Deutch, AY | 1 |
| Haber, S | 1 |
| Rodríguez-Puyol, D | 1 |
| Alsasua, A | 1 |
| Santos, JC | 1 |
| Blanchart, A | 1 |
| López-Novoa, JM | 1 |
| Doppman, JL | 1 |
| Sershen, H | 1 |
| Hashim, A | 1 |
| Lajtha, A | 1 |
6 reviews available for homovanillic acid and Disease Models, Animal
| Article | Year |
|---|---|
Pathogenesis of schizophrenia: Part II. Temporo-frontal two-step hypothesis.
Topics: Amygdala; Animals; Disease Models, Animal; Dopamine; Entorhinal Cortex; Frontal Lobe; Homovanillic A | 2003 |
Renal dopaminergic mechanisms in renal parenchymal diseases and hypertension.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Blood Pressure; Disease Models, Animal; Dopamine; Homovanil | 2001 |
Brain nervous mechanisms involved in the so-called extra pyramidal motor and psychomotor disturbances.
Topics: Animals; Athetosis; Basal Ganglia Diseases; Brain; Brain Stem; Cats; Corpus Striatum; Disease Models | 1975 |
[Current biochemical conceptions of mental disorders. I. Biogenic amines in the pathogenesis of schizophrenia].
Topics: Animals; Biogenic Amines; Blood Platelets; Brain Chemistry; Catechol O-Methyltransferase; Disease Mo | 1979 |
The striopallidal system: Its implication in motor disorders.
Topics: Animals; Basal Ganglia Diseases; Cats; Corpus Striatum; Disease Models, Animal; Dopamine; Extrapyram | 1975 |
Human aggression and suicide.
Topics: Adolescent; Adult; Aggression; Animals; Depressive Disorder; Disease Models, Animal; Female; Grief; | 1986 |
189 other studies available for homovanillic acid and Disease Models, Animal
| Article | Year |
|---|---|
Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.
Topics: Animals; Biological Transport; Blood-Brain Barrier; Capillaries; Disease Models, Animal; Estrone; Ma | 2004 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
[Effect of Rehmanniae Radix on depression-like behavior and hippocampal monoamine neurotransmitters of chronic unpredictable mild stress model rats].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents; Chromatography, Liquid; Depression; | 2022 |
Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Corpus Striatum; Disease Models, Ani | 2023 |
Protective Effect of Hemin Against Experimental Chronic Fatigue Syndrome in Mice: Possible Role of Neurotransmitters.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anxiety; Behavior, Animal; Brain; Disease Models, Animal; D | 2020 |
Preventive role of regular low-intensity exercise during adolescence in schizophrenia model mice with abnormal behaviors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Behavior, Animal; Disease Models, Animal; Dopa | 2021 |
Antidepressant-Like Effect of the Endogenous Neuroprotective Amine, 1MeTIQ in Clonidine-Induced Depression: Behavioral and Neurochemical Studies in Rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Biogenic Monoamines; Brain; Brain Che | 2017 |
Preliminary Analysis of Parkinson-like Motor Coordination Abnormityin Brain-specific hS100B Transgenic Mice.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; G-Protein-Coupled Receptor Kinase 2; Homovanillic | 2017 |
Trace amine-associated receptor 1 regulation of methamphetamine-induced neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Body Temperature Regulation; Brain; Ce | 2017 |
Myopia induced by flickering light in guinea pig eyes is associated with increased rather than decreased dopamine release.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Axial Length, Eye; Blotting, Western; Chromatography, High | 2017 |
Peripheral Administration of Tetanus Toxin Hc Fragment Prevents MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2018 |
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Disease Models, Animal; Gene Expression | 2018 |
Preliminary validation of natural depression in macaques with acute treatments of the fast-acting antidepressant ketamine.
Topics: Animals; Antidepressive Agents; Conditioning, Operant; Depressive Disorder; Disease Models, Animal; | 2019 |
Systems analysis of genetic variation in MPTP neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Brain; Disease Models, Animal; Dopamine; Gene E | 2013 |
GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Animals; Disease Models, Animal; Diz | 2013 |
Assessment of the abuse potential of MDMA in the conditioned place preference paradigm: role of CB1 receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain; Conditioning, Operant; Disease | 2013 |
The subthalamic activity and striatal monoamine are modulated by subthalamic stimulation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Action Potentials; Animals; Biogenic Monoamines; Chromatography, Hig | 2014 |
Autistic-like behavioural and neurochemical changes in a mouse model of food allergy.
Topics: Age Factors; Animals; Autistic Disorder; Biogenic Monoamines; Brain; Chromatography, High Pressure L | 2014 |
Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; alpha-Synuclein; Amyloid; Animals; Corpu | 2014 |
Predator exposure/psychosocial stress animal model of post-traumatic stress disorder modulates neurotransmitters in the rat hippocampus and prefrontal cortex.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cats; Disease Models, Animal; Hippocampus; Homovanillic Aci | 2014 |
Astrocytic JWA expression is essential to dopaminergic neuron survival in the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Carrier Proteins; Cell Line; Cell Survival; Dis | 2014 |
Acute pancreatitis affects the metabolism of catecholamine neurotransmitters in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acute Disease; Animals; Catecholamines; Cerebellum; Corpus Striatum; | 2014 |
Dietary supplementation with resveratrol protects against striatal dopaminergic deficits produced by in utero LPS exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dietary Supplements; Disease Models, Anima | 2014 |
Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2014 |
Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum.
Topics: Aged; Aged, 80 and over; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Uptake | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; | 2015 |
A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Mo | 2014 |
High-anxiety rats are less sensitive to the rewarding affects of amphetamine on 50kHz USV.
Topics: Amphetamine; Analysis of Variance; Animals; Anxiety; Central Nervous System Stimulants; Conditioning | 2014 |
Dual regulating effects of gastrodin on extracellular dopamine concentration in rats models of Tourette's syndrome.
Topics: Animals; Apomorphine; Benzyl Alcohols; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine P | 2015 |
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autophagy; Corpus Striatum; Disease Models, Animal; Disease | 2015 |
AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Dependovirus; Disease Models, Animal; Do | 2015 |
Dietary long chain n-3 polyunsaturated fatty acids prevent impaired social behaviour and normalize brain dopamine levels in food allergic mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Chymases; Diet; Disease Models, Animal; Docosahexaen | 2015 |
Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Chromatography, High Pressure Liquid; Di | 2015 |
Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetophenones; Animals; Cytokines; Disease Models, Animal; Dopaminer | 2016 |
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; DNA | 2015 |
Neonatal aphakia is associated with altered levels of dopamine metabolites in the non-human primate retina.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Aphakia, Postcataract; Axial Length, Eye; | 2015 |
High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).
Topics: Administration, Oral; Animals; Biopterins; Brain; Disease Models, Animal; Dopamine; Genotype; Homova | 2016 |
Convergent evidence from alcohol-dependent humans and rats for a hyperdopaminergic state in protracted abstinence.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Alcohol Abstinence; Alcoholism; Animals; Benzazepines; | 2016 |
MPTP neurotoxicity is highly concordant between the sexes among BXD recombinant inbred mouse strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2016 |
The effects of reduced dopamine transporter function and chronic lithium on motivation, probabilistic learning, and neurochemistry in mice: Modeling bipolar mania.
Topics: Animals; Bipolar Disorder; Brain Chemistry; Conditioning, Operant; Disease Models, Animal; Dopamine | 2017 |
Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chlorocebus aethiops; Corpus Striatum; Di | 2008 |
[Effect and mechanism on dopamine contents of striatum in rat model of Parkinson's disease ginsenoside Rg1].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Central Nervous System Agents; Corpus Str | 2008 |
An insight on the neuropharmacological activity of Telescopium telescopium--a mollusc from the Sunderban mangrove.
Topics: Animals; Behavior, Animal; Body Temperature; Brain; Central Nervous System Depressants; Disease Mode | 2008 |
Dopamine and serotonin release in the nucleus accumbens during starvation-induced hyperactivity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Body Temperature; Body Weight; Chroma | 2009 |
In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Central Nervous System Agents; Chroma | 2009 |
Behavioral and neurochemical profile of m-CPP following exposure to single restraint stress in rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Chromatography, High Pre | 2009 |
Central l-proline attenuates stress-induced dopamine and serotonin metabolism in the chick forebrain.
Topics: Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Chickens; Chromatography, High Pr | 2009 |
Prenatal methamphetamine exposure affects the mesolimbic dopaminergic system and behavior in adult offspring.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Disease Mod | 2009 |
Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain Chemistry; Cell Division; Chrom | 2010 |
Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Glutathione; Glutathione | 2009 |
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2009 |
Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomechanical Phenomena; Chromatography, High | 2010 |
Biochemical alteration in cerebrospinal fluid precedes behavioral deficits in Parkinsonian rats induced by 6-hydroxydopamine.
Topics: Animals; Biomarkers; Cell Count; Cell Death; Disease Models, Animal; Dopamine; Homovanillic Acid; Hy | 2009 |
Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo.
Topics: Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedu | 2010 |
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Analysis of Variance; Animals; Brain; Cell Count; | 2010 |
Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2009 |
Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; C | 2010 |
Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2010 |
Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Birth | 2010 |
Modeling Parkinson's disease genetics: altered function of the dopamine system in Adh4 knockout mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Amphetamine; Analysis of Variance; Animals; A | 2011 |
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Analysis of Variance; Animals; Behavior, Animal; Brain | 2011 |
Apolipoprotein D mediates autocrine protection of astrocytes and controls their reactivity level, contributing to the functional maintenance of paraquat-challenged dopaminergic systems.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Apolipoproteins D; Apoptosis; Astrocytes; | 2011 |
Heat shock protein 70 kDa over-expression and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal degeneration in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dise | 2011 |
Effects of oxcarbazepine on monoamines content in hippocampus and head and body shakes and sleep patterns in kainic acid-treated rats.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Dopamine; Hippocampus; Homovanillic | 2011 |
Chronic progesterone treatment of male rats with unilateral 6-hydroxydopamine lesion of the dorsal striatum exacerbates [corrected] parkinsonian symptoms.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Res | 2011 |
Behavioural and physiological correlates of impulsivity in the domestic dog (Canis familiaris).
Topics: Aggression; Animals; Choice Behavior; Chromatography, High Pressure Liquid; Conditioning, Operant; D | 2012 |
Stress-induced cross-sensitization to amphetamine is related to changes in the dopaminergic system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Amphetamines; Analysis of Variance; Animals; Animals, N | 2012 |
Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Analysis of Variance; Animals; Apomorphine; C | 2012 |
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Anima | 2012 |
Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Atrophy; Brain Injuries; Calcium-Binding Proteins; Carrier | 2012 |
Protective effect of extract of Acanthopanax senticosus Harms on dopaminergic neurons in Parkinson's disease mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Caspase 3; Chromatog | 2012 |
Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Chroma | 2012 |
Prostaglandin E2-mediated attenuation of mesocortical dopaminergic pathway is critical for susceptibility to repeated social defeat stress in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Benzazepines; Calcium-Binding Protein | 2012 |
Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Age Factors; Aging; An | 2012 |
Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neuro | 2013 |
Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Data | 2013 |
Forced nonuse in unilateral parkinsonian rats exacerbates injury.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Casts, Surg | 2002 |
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 2002 |
Circadian rhythmicity in dopamine content of mammalian retina: role of the photoreceptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Circadian Rhythm; Dis | 2002 |
Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Antiparkinson Agents; Behavior, Animal; Corpus | 2002 |
Dose-dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Ascorbic Acid; Behavior, Animal; Brain; Disea | 2003 |
Characterization of monoaminergic systems in brain regions of prematurely ageing mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging, Premature; Animals; Brain; Disease Models, Animal; Dopamine; | 2003 |
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; | 2003 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ditiocarb; Dopamine; | 2003 |
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2003 |
3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationshi | 2003 |
Alteration of striatal dopaminergic function induced by glioma development: a microdialysis and immunohistological study in the rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Afferent Pathways; Animals; Brain Neoplasms; Disease Models, Animal; | 2004 |
Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 2004 |
Dopamine overflow is increased in olfactory bulbectomized rats: an in vivo microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia; Disease Models, Animal; Dopamine; Explorator | 2004 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal | 2004 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; | 2004 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; | 2004 |
The control of feather pecking by serotonin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aggression; Animals; Behavior, Animal; Brain; Brain Chemistry; Chick | 2004 |
Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Methyltyrosine; | 2004 |
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Cabergoline; Carbidopa; Caspases; Dis | 2005 |
Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Anima | 2005 |
Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acetates; Animals; Die | 2004 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; | 2005 |
Neuroprotection by crocetin in a hemi-parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Carotenoids; Catala | 2005 |
Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model for early-onset dystonia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age of Onset; Animals; Brain; Chromatography, High Pressure Liquid; | 2005 |
Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Curcumin; Disease Models, Animal; Dopamine; F | 2005 |
Cerebellar neurotransmission in attention-deficit/hyperactivity disorder: does dopamine neurotransmission occur in the cerebellar vermis?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2006 |
Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: restoration of bilateral food retrieval by dopamine receptor agonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Chromatogra | 2006 |
Fibroblast growth factor receptor signaling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice.
Topics: Animals; Cell Differentiation; Cell Enlargement; Disease Models, Animal; Dopamine; Dopamine Plasma M | 2006 |
Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Nor | 2006 |
Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cerebral Cortex; Chromatography, High Pre | 2006 |
A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse: effects in laboratory rat models relating to addiction.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Cocaine; Dialysis; | 2006 |
Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Central Nervous System Depressants; Chromatography, High Pr | 2007 |
Dehydroepiandrosterone in the nucleus accumbens is associated with early onset of depressive-behavior: a study in an animal model of childhood depression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age of Onset; Animals; Biogenic Monoamines; Child; Dehydroepiandrost | 2007 |
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Ben | 2008 |
The reward system and maternal behavior in an animal model of depression: a microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Animals, Newborn; Behavior, Animal; Body Weigh | 2008 |
[Roles of fluoxetine and haloperidol in mouse models of DOI-induced head twitch response].
Topics: Amphetamines; Animals; Disease Models, Animal; Dopamine; Fluoxetine; Haloperidol; Homovanillic Acid; | 2007 |
Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain-Derived Neurotrophic Factor; Disease Models, A | 2008 |
Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Cytoprotectio | 2008 |
Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationshi | 2008 |
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Animals, Newborn; Cell Count; Disease | 2008 |
Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Stem; Disease Models, Animal; Dopa Decarboxylase; Dop | 1980 |
Narcolepsy: biogenic amine deficits in an animal model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Disease Models, Animal; Dogs; Dopamine; Ep | 1983 |
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Disease Models, Anima | 1983 |
Cerebrospinal fluid measures of neurotransmitter changes associated with pharmacological alteration of the despair response to social separation in rhesus monkeys.
Topics: alpha-Methyltyrosine; Animals; Anxiety, Separation; Behavior, Animal; Depressive Disorder; Disease M | 1984 |
Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Homovani | 1980 |
An animal model of early-treated PKU.
Topics: Animals; Animals, Newborn; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combination; Fetu | 1994 |
Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Frontal | 1995 |
Levels of dopamine and its metabolites in the extracellular medium of the striatum of newborn piglets during graded hypoxia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Corpus Striatum; Disease Models, Animal; | 1994 |
Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1993 |
Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biopterins; Brain Diseases; Carbidopa; Corpus Striatum; Cyc | 1993 |
Depletion of mesolimbic dopamine during behavioral despair: partial reversal by chronic imipramine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Depression; Disease Models, Animal; Dopami | 1993 |
Tyrosine uptake and regional brain monoamine metabolites in a rat model resembling congenital hyperammonemia.
Topics: Amino Acids; Ammonia; Animals; Body Weight; Brain; Disease Models, Animal; Dopamine; Eating; Homovan | 1996 |
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 1996 |
A nonhuman primate model of type II excessive alcohol consumption? Part 1. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentrations and diminished social competence correlate with excessive alcohol consumption.
Topics: Adult; Affect; Age Factors; Alcohol Drinking; Alcoholism; Animals; Arousal; Disease Models, Animal; | 1996 |
Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Catecholamines; Cell | 1997 |
Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1997 |
Oxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Corpus Striatum; Cycloheximide; Disease Model | 1998 |
Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; | 1998 |
Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; B | 1998 |
Prefrontal and striatal dopamine metabolism during enhanced rebound hyperphagia induced by space restriction--a rat model of binge eating.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bulimia; Chromatography, High Pressure Liquid; Disease Mode | 1998 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Ago | 1999 |
Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1999 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chlorocebus aethiops; Disea | 2000 |
Differential effects of L-trytophan and buspirone on biogenic amine contents and metabolism in Lurcher mice cerebellum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Buspirone; Cerebellar Ataxia; Cerebellum; | 2000 |
Cerebral oligaemia episode triggers free radical formation and late cognitive deficiencies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aspartic Acid; Carotid Stenosis; Cognition Disorders; Corpu | 2000 |
Neonatal lesions of the left entorhinal cortex affect dopamine metabolism in the rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amygdala; Animals; Animals, Newborn; Brain; Caudate Nucleus; Disease | 2000 |
Dramatic brain aminergic deficit in a genetic mouse model of phenylketonuria.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amygdala; Animals; Biogenic Monoamines; Brain; Caudate Nucleus; Dise | 2000 |
Dopamine D(1) and D(2) receptors in the forebrain of dystonia musculorum mutant mice: an autoradiographic survey in relation to dopamine contents.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Benzazepines; Cerebellar Ataxia; Disease M | 2000 |
Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenal Medulla; Animals; Antiparkinson Agents; Apomorphine; Capsule | 2000 |
Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Proteins; Cell Count; Corpus Striatum; Disease Mode | 2000 |
Prevention of dopaminergic neurotoxicity by targeting nitric oxide and peroxynitrite: implications for the prevention of methamphetamine-induced neurotoxic damage.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Chromatography, High Pressure Liquid; | 2000 |
Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Area Under Curve; Body Temperature; Central Nervous | 2000 |
Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Prote | 2001 |
Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2001 |
IGF-I and bFGF improve dopamine neuron survival and behavioral outcome in parkinsonian rats receiving cultured human fetal tissue strands.
Topics: Abortion, Induced; Animals; Apomorphine; Brain; Brain Tissue Transplantation; Cell Survival; Cells, | 2001 |
Hyperactivity and impaired response habituation in hyperdopaminergic mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamines; Animals; Apomorphine; Attention Deficit Disorder with | 2001 |
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents, Non- | 2001 |
Limbic dopaminergic adaptation to a stressful stimulus in a rat model of depression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adaptation, Physiological; Animals; Depression; Disease Models, Anim | 2001 |
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Temperature; Casts, Sur | 2001 |
Opposite genotype-dependent mesocorticolimbic dopamine response to stress.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Depression; Disease Models, Animal; Dopam | 2001 |
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 2001 |
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Do | 2001 |
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; | 2001 |
Behavioral consequences of methamphetamine-induced neurotoxicity in mice: relevance to the psychopathology of methamphetamine addiction.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine-Related Disorders; Animals; Behavior, Animal; Binding Si | 2002 |
Adaptation to repeated cocaine administration in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Cocaine; Cocaine-Related Disorders; Cortic | 2002 |
Neurochemical investigation of an endogenous model of the "hyperkinetic syndrome" in a hybrid dog.
Topics: Adenylyl Cyclases; Amphetamine; Animals; Brain; Caudate Nucleus; Disease Models, Animal; Dogs; Dopam | 1979 |
Catecholamines and neurologic diseases (first of two parts).
Topics: Animals; Brain; Catecholamines; Cerebrospinal Fluid; Disease Models, Animal; Homovanillic Acid; Huma | 1975 |
The olive babbon (Papio anubis) as an animal model for research in affective disorders of man.
Topics: Affective Symptoms; Animals; Biogenic Amines; Brain; Chlorpromazine; Disease Models, Animal; Haplorh | 1977 |
Animal models for tardive dyskinesia: effects of thioridazine.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Homovanillic A | 1977 |
Virus infections in infant mice causing persistent impairment of turnover of brain catecholamines.
Topics: Age Factors; Animals; Animals, Newborn; Body Weight; Brain; Catecholamines; Coxsackievirus Infection | 1975 |
Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine.
Topics: Animals; Apomorphine; Chlorpromazine; Clozapine; Corpus Striatum; Dibenzazepines; Dibenzoxazepines; | 1975 |
Cinnarizine-induced parkinsonism in primates.
Topics: Animals; Biogenic Monoamines; Cinnarizine; Disease Models, Animal; Dopamine; Haplorhini; Homovanilli | 1992 |
Biogenic amines distribution in the brain of nervous and normal pointer dogs. A genetic animal model of anxiety.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anxiety; Biogenic Amines; Brain Chemistry; Disease Models, | 1990 |
Behavioral recovery from MPTP-induced parkinsonism in monkeys after intracerebral tissue implants is not related to CSF concentrations of dopamine metabolites.
Topics: Adrenal Medulla; Amnion; Animals; Brain Tissue Transplantation; Caudate Nucleus; Disease Models, Ani | 1990 |
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1991 |
Neuropeptide changes in a primate model (Cebus apella) for tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Cebus; Corpus Striatum; | 1990 |
Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Brain; | 1990 |
Catecholaminergic responses to rotational stress in rat brain stem: implications for amphetamine therapy of motion sickness.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Brain Stem; Disease Models, Animal; Homovanill | 1990 |
Neurotransmitter changes in cerebrospinal fluid in the Spanish toxic oil syndrome: human clinical findings and experimental results in mice.
Topics: Anilides; Animals; Brain Chemistry; Brassica; Catecholamines; Disease Models, Animal; Foodborne Dise | 1986 |
Contents of monoamines in forebrain regions of alcohol-preferring (P) and -nonpreferring (NP) lines of rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Alcoholism; Animals; Biogenic Amines; Brain; Cereb | 1987 |
The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucle | 1985 |
Experimental tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Brain; Cebus; Corpus Striatum; Disease Models, Animal; Drug Evaluatio | 1985 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not destroy nigrostriatal neurons in the scorbutic guinea pig.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid | 1985 |
Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorocebus aethiops; Disease Models, Animal; | 1986 |
Plasma catecholamines and urinary excretion of their main metabolites in three models of portal hypertension.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamines; Disease Models, Animal; Dopamine; Homovanil | 1988 |
Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Brain; Brain Chemistry; Carbidop | 1986 |
Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |
Influence of changes in brain monoamine metabolism on behaviour of herpes simplex-infected mice.
Topics: Aggression; Animals; Apomorphine; Behavior, Animal; Brain; Clonidine; Dihydroxyphenylalanine; Diseas | 1974 |